We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., March 11, 2024 ROCKVILLE, Md., March 11, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it wil...
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants PR Newswire ROCKVILLE, Md., March 6, 2024 ROCKVILLE, Md., March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (N...
REGENXBIO Announces Proposed Public Offering of Common Stock PR Newswire ROCKVILLE, Md., March 6, 2024 ROCKVILLE, Md., March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.6 | -2.61665939817 | 22.93 | 23.325 | 21.25 | 856981 | 22.13357633 | CS |
4 | 3.65 | 19.539614561 | 18.68 | 28.8 | 17.12 | 1056603 | 21.65631479 | CS |
12 | 3.43 | 18.1481481481 | 18.9 | 28.8 | 11.83 | 822262 | 18.25550011 | CS |
26 | 4.54 | 25.5199550309 | 17.79 | 28.8 | 11.83 | 632710 | 17.93260546 | CS |
52 | 2.17 | 10.7638888889 | 20.16 | 28.8 | 11.83 | 509428 | 18.3025979 | CS |
156 | -16.98 | -43.1951157466 | 39.31 | 46.46 | 11.83 | 431710 | 25.10523087 | CS |
260 | -36.43 | -61.9979577944 | 58.76 | 63.21 | 11.83 | 444148 | 31.63780039 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: 1-888-992-3836 | help@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |